trial

Cognitive Biases Under Ketamine

NCTId NCT02235012
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 84 (actual)
Sponsored by Centre Hospitalier St Anne
Primary completion 2022-04-28
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
84 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2014-09-08
Primary completion
2022-04-28
Eligibility
ALL · 18 Years · 39 Years

Interventions & indications

Drugs
Ketamine

Sponsors

Centre Hospitalier St AnneLead Sponsor
Fondation pour la Recherche MédicaleCollaborator
Fondation FyssenCollaborator
Comité pour la Recherche Hospitalière MédicaleCollaborator
Association Schizo OuiCollaborator

Investigators

1
Raphaël GAILLARD, MD, PhDPrincipal Investigator

Sites

1 total
Paris, France

Facts & assertions

4 sourced
Enrollment
84
Phase
NA
Primary Completion Date
2022-04-28
Status
COMPLETED
relationships
The graph out of here
drug
Ketamine
drug
lead_sponsor
Centre Hospitalier St Anne
company
collaborator
Fondation pour la Recherche Médicale
company
Fondation Fyssen
company
indication
Schizophrenia
indication
Healthy Subjects
indication
investigator
Raphaël GAILLARD, MD, PhD
person